Treatment of multiple myeloma has substantially changed over the past decade with the
introduction of several classes of new effective drugs that have greatly improved the rates …

Assessment of minimal residual disease (MRD) is becoming standard diagnostic care for
potentially curable neoplasms such as acute lymphoblastic leukemia. In multiple myeloma …

Background Therapeutic resistance occurs in most patients with multiple myeloma (MM).
One of the key mechanisms for MM drug resistance comes from the interaction between MM …

MYC contributes to the pathogenesis of a majority of human cancers, yet strategies to
modulate the function of the c-Myc oncoprotein do not exist. Toward this objective, we have …

Purpose To perform a critical analysis on the impact of depth of response in newly
diagnosed multiple myeloma (MM). Patients and Methods Data were analyzed from 609 …

PURPOSE Patients with multiple myeloma (MM) may show patchy bone marrow (BM)
infiltration and extramedullary disease. Notwithstanding, quantification of plasma cells (PCs) …

Monoclonal gammopathy of undetermined significance (MGUS) is a premalignant plasma-
cell proliferative disorder associated with a life-long risk of progression to multiple myeloma …

We analyzed whole genomes of unique paired samples from smoldering multiple myeloma
(SMM) patients progressing to multiple myeloma (MM). We report that the genomic …

Multiple myeloma is a plasma cell malignancy characterized by complex heterogeneous
cytogenetic abnormalities. The bone marrow microenvironment promotes multiple myeloma …

Mechanisms of constitutive NF-κB signaling in multiple myeloma are unknown. An inhibitor
of IκB kinase β (IKKβ) targeting the classical NF-κB pathway was lethal to many myeloma …